Atnm Yahoo Finance (2024)

FAQs

What is the projection for ATNM stock? ›

Based on short-term price targets offered by five analysts, the average price target for Actinium Pharmaceuticals comes to $9.52. The forecasts range from a low of $2.00 to a high of $25.00. The average price target represents an increase of 378.39% from the last closing price of $1.99.

Actinium Pharmaceuticals has 151.26% upside potential, based on the analysts' average price target. Is ATNM a Buy, Sell or Hold? Actinium Pharmaceuticals has a consensus rating of Strong Buy which is based on 3 buy ratings, 1 hold ratings and 0 sell ratings.

On average, Wall Street analysts predict that Actinium Pharmaceuticals's share price could reach $13.75 by Aug 6, 2025. The average Actinium Pharmaceuticals stock price prediction forecasts a potential upside of 623.68% from the current ATNM share price of $1.90.

shares dropped 64% to $2.2001. On Monday, the FDA determined that Actinium Pharmaceuticals' Phase 3 SIERRA trial is not adequate to support a Biologics License Application (BLA) filing for Iomab-B despite its statistically significant primary endpoint.

According to analysts, PATH price target is 15.81 USD with a max estimate of 19.00 USD and a min estimate of 14.00 USD.

According to analysts, PERI price target is 9.33 USD with a max estimate of 10.00 USD and a min estimate of 9.00 USD.

The Board of Directors approved the reverse stock split at a ratio of 1-for-30 on August 7, 2020. Stockholders of record will be receiving information regarding their share ownership following the reverse stock split from the Company's transfer agent, Action Stock Transfer.

Cash on Hand as of March 2024 : $84.05 M.

Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. The Company develops antibody radiation conjugates (ARCs) and other targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet medical needs.

What is the stock price prediction for Raytheon in 2025? ›

According to analysts, RTX price target is 121.55 USD with a max estimate of 142.00 USD and a min estimate of 101.00 USD.

Eli Lilly (LLY) Stock Price Prediction in 2025

Of the 26 analysts covering Eli Lilly stock, the current rating is 1.71 or “Outperform” with 1-year price targets as high as $1,100 and as low as $540.00.

Actinium's most stable isotope, actinium-227, has a half-life of 21.77 years. It decays into francium-223 through alpha decay or into thorium-227 through beta decay. Actinium has no significant commercial applications, although it is used in the production of neutrons.

The average one-year price target for Actinium Pharmaceuticals, Inc. is $5.92. The forecasts range from a low of $2.02 to a high of $10.29. A stock's price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings.

227Ac is about a hundred and fifty times as radioactive as radium making a valuable as the neutron source of energy. Although actinium is found in trace of amounts in uranium ore, more commonly it is synthesised in milligram amounts by the neutron irradiation of radium-226 in a nuclear reactor.

Based on short-term price targets offered by 27 analysts, the average price target for Vertex Pharmaceuticals comes to $506.11. The forecasts range from a low of $325.00 to a high of $600.00. The average price target represents an increase of 2.59% from the last closing price of $493.35.

On average, Wall Street analysts predict that Inovio Pharmaceuticals's share price could reach $23.20 by Aug 12, 2025. The average Inovio Pharmaceuticals stock price prediction forecasts a potential upside of 252.85% from the current INO share price of $6.58.

The average price target for Immunome is $31.33. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $38.00 ,the lowest forecast is $23.00. The average price target represents 101.74% Increase from the current price of $15.53.